B+
Bull case
20%
Probability
Target price
$5.50
+27.3% vs current
EDAP
EDAP TMSBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$3.60
-16.7% vs current
B-
Bear case
25%
Probability
Target price
$2.00
-53.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+31.4
Score
AI commentary
Sentiment is mildly constructive but cautious. Primary sources support a credible Focal One adoption narrative and a near-term liquidity event, yet the current setup still looks more like a monitoring thesis than a clean re-rating: evidence quality is modest, catalyst density is thin, and worsening losses offset the positive revenue mix shift [#PR-2026-03-25][#8-K-2026-04-02][#10-K-2026-03-25].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-30eventLate-April 2026 EIB Tranche B fundingHigh impact
EDAP requested the €12.0 million Tranche B draw on April 1, 2026 and said disbursement is expected in late April 2026; that should improve near-term liquidity, though it also comes with 1,116,244 warrants at a €3.23 strike [#8-K-2026-04-02].
2026-06-01catalystAUA meeting and June 1 Investor Day could test demand narrativeHigh impact
Management flagged the May 15-18, 2026 AUA meeting, a June 1, 2026 Investor Day, and a June 2-4, 2026 healthcare conference; these events are the clearest near-term checkpoints for whether strong Focal One placement and procedure trends are sustaining into 2026 [#PR-2026-03-25].
2026-12-31catalyst2026 HIFU growth must offset ongoing losses and cash burnHigh impact
EDAP reiterated 2026 revenue guidance of $72.0 million-$80.0 million, with core HIFU revenue expected at $50.0 million-$54.0 million, or 34%-45% growth, after 39% HIFU growth in 2025; however, the same release showed a 2025 net loss of €25.9 million and cash of €17.4 million at year-end, so execution must translate into better operating leverage rather than just placements [#PR-2026-03-25][#10-K-2026-03-25].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology